Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Monoclonal nephritic factors reveal insights into C3 convertase dynamics and dysregulation.

bioRxiv : the preprint server for biology·2026

Same author

Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy.

The New England journal of medicine·2026

Same author

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons.

Advances in therapy·2026

Same author

Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative GN: Phase 3 VALIANT Subgroup Analysis.

Clinical journal of the American Society of Nephrology : CJASN·2026

Same author

Complement 3 Glomerulopathy (C3G) in Native and Posttransplant Kidneys: A Review.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2026

Same author

Complement biomarkers during iptacopan treatment - Authors' reply.

Lancet (London, England)·2026

Same journal

New Drugs on the Horizon for Hypertension.

Advances in kidney disease and health·2026

Same journal

Hyperammonemia Physiology and Management: A Nephrology-Centered Review.

Advances in kidney disease and health·2026

Same journal

Hypertension in Advanced Chronic Kidney Disease: Saving the Kidneys or the Heart?

Advances in kidney disease and health·2026

Same journal

Social Determinants of Health and Primary Hypertension in Children and Adolescents: Proposed Solutions Using a Socioecological Model of Health.

Advances in kidney disease and health·2026

Same journal

Blood Pressure Management in the Inpatient and Acute Care Setting.

Advances in kidney disease and health·2026

Same journal

Endocrine Hypertension in Children and Adults: Beyond Primary Aldosteronism.

Advances in kidney disease and health·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 21, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Update on C3 Glomerulopathy.

Benjamin Wooden¹, Carla M Nester², Andrew S Bomback¹

¹Division of Nephrology, Department of Medicine, Columbia University, New York, NY.

Advances in Kidney Disease and Health

|July 14, 2024

Summary

This summary is machine-generated.

C3 glomerulopathy (C3G) is a rare kidney disease caused by complement system dysregulation. New anticomplement therapies are in development, offering hope for improved treatment options for this condition.

More Related Videos

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments

Published on: April 24, 2020

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

Related Experiment Videos

Last Updated: Jun 21, 2025

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments

Published on: April 24, 2020

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

Area of Science:

Nephrology
Immunology
Complement System Biology

Background:

C3 glomerulopathy (C3G) is a rare kidney disease characterized by C3 deposition in glomeruli.
It results from alternative complement pathway dysregulation due to genetic or acquired factors.
C3G causes glomerular damage, leading to nephritic and nephrotic syndromes with poor prognosis.

Purpose of the Study:

To provide an overview of C3 glomerulopathy.
To summarize current treatment evidence for C3G.
To detail ongoing clinical trials for C3G.

Main Methods:

Review of existing literature on C3 glomerulopathy.
Analysis of current therapeutic strategies.
Compilation of data from ongoing clinical trials.

Main Results:

Understanding of C3G mechanisms and lesions has advanced significantly.
Treatment options for C3G remain limited.
Several anticomplement therapies are in late-stage clinical trials.

Conclusions:

Anticomplement therapies show promise for C3G treatment.
Targeted treatment options are expected soon.
Ongoing trials are crucial for advancing C3G management.